This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ProQR's Genetic Disorder Candidate Gets Orphan Drug Status
by Zacks Equity Research
ProQR Therapeutics (PRQR) announced that its investigational dystrophic epidermolysis bullosa candidate, QR-313, was granted orphan drug designation by the FDA.
Teva/Nuvelution to Speed Up Development of Austedo in US
by Zacks Equity Research
Teva Pharma (TEVA) and Nuvelution inked a deal to accelerate the development of Austedo (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome.
Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia
by Zacks Equity Research
Alkermes (ALKS) announced encouraging results from a phase IV study of ARISTADA for the treatment of schizophrenia.
Pluristem's Ischemia Candidate Gets Fast Track Designation
by Zacks Equity Research
Pluristem Therapeutics' (PSTI) phase III study of PLX-PAD cells in patients with critical limb ischemia granted Fast Track designation by the FDA.
Zacks.com featured highlights include include Hasbro, Regeneron Pharmaceuticals, Applied Materials, Vantiv, and CBRE Group
by Zacks Equity Research
Zacks.com featured highlights include include Hasbro, Regeneron Pharmaceuticals, Applied Materials, Vantiv, and CBRE Group
Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU
by Zacks Equity Research
Glaxo's (GSK) single inhaler triple therapy for the treatment of COPD in patients who are already being treated with a ICS/LAMA combination received a positive opinion from the CHMP in the EU.
5 Top Stocks with Impressive Sales Growth Worth Betting On
by Zacks Equity Research
Steady sales growth is the key to survival for any business. Also, it is an important tool for making investment decisions.
Pfizer Xtandi Succeeds in Early Stage Prostate Cancer Study
by Zacks Equity Research
Pfizer's (PFE) prostate cancer drug Xtandi met the primary endpoint in a late-stage study, which can expand the label of the drug to include early-stage patients.
Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study
by Zacks Equity Research
Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.
Glaxo's Shingles Candidate Gets Positive FDA Committee Vote
by Zacks Equity Research
Glaxo (GSK) declared that an FDA advisory panel has unanimously voted recommending approval for its shingles vaccine candidate, Shingrix, in older patients.
Alexion (ALXN) Reports Interim Results for Soliris Study
by Zacks Equity Research
Alexion (ALXN) announced results from an interim analysis of an ongoing phase III REGAIN study of Soliris. The study showed sustained treatment benefits of Soliris treatment for patients with refractory generalized myasthenia gravis.
Alexion to Restructure Operations, to Lower Headcount by 20%
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) announced that it will undertake a restructuring plan to re-align the global organization and cut workforce.
Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data
by Arpita Dutt
Key highlights include Alexion's (ALXN) restructuring plans and promising data from Kura Oncology on its lead pipeline candidate.
Achillion's HCV Partnership with J&J Terminated, Stock Falls
by Zacks Equity Research
Achillion Pharmaceuticals (ACHN) suffered a setback as Janssen terminated their worldwide license and collaboration arrangement on hepatitis C.
AstraZeneca's Asthma Candidate Shows Promising Results
by Zacks Equity Research
AstraZeneca's asthma candidate, benralizumab, showed promising results in patients who experience more frequent exacerbations despite being on standard-of-care medicines.
Pfizer Lung Cancer Drug's Overall Survival Data Unfavorable
by Zacks Equity Research
Pfizer (PFE) announced final overall survival data from a phase III study (PROFILE 1014), evaluating its cancer drug Xalkori for first-line treatment of ALK-positive non-small cell lung cancer (NSCLC).
AstraZeneca's Lung Cancer Study Data Promising, Shares Spike
by Zacks Equity Research
AstraZeneca, (AZN) releases data from a late-stage study on Imfinzi which showed that the new cancer drug led to superior progression-free survival to standard of care in lung cancer patients.
Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi's (SNY) Dupixent (dupilumab) met two primary endpoints in phase III study.
Roche's Ophthalmology Drug Fails to Meet Primary Endpoint
by Zacks Equity Research
Roche's (RHHBY) share price declined after its ophthalmology candidate, lampalizumab, failed to meet the primary endpoint in phase III Spectri study.
5 Top-Ranked Biotech Stocks to Buy Right Now
by Arpita Dutt
If you are looking to invest in the biotech sector, here is a peek at 5 buy-ranked biotech stocks including Regeneron Pharmaceuticals (REGN).
Top Ranked Momentum Stocks to Buy for September 11th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 11th:
AbbVie's Upadacitinib Meets Primary Endpoint in Phase IIb
by Zacks Equity Research
AbbVie's (ABBV) eczema candidate upadacitinib meets primary endpoints in a phase IIb trial for treating atopic dermatitis. The company aims to advance the candidate to the next study level in 2018.
Regeneron's Cemiplimab Gains Breakthrough Therapy Status
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi's skin cancer candidate cemiplimab gets the FDA-granted Breakthrough Therapy status. The companies also anticipate submitting a BLA in the first-quarter 2018.
Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth
by Zacks Equity Research
Lilly (LLY) plans to reduce its global workforce by approximately 3,500 positions, which should save $500 million. Lilly plans to invest the savings in new drugs and overall growth of the company.
AstraZeneca's COPD Candidate Duaklir Reports Positive Data
by Zacks Equity Research
AstraZeneca Plc (AZN) announced encouraging results from the phase III AMPLIFY study for Duaklir being developed for the treatment of chronic obstructive pulmonary disease (COPD).